Find Clinical Trials & Studies

Visit the Research & Education Institute

Casdatifan and Cabozantinib vs Placebo and Cabozantinib in Patients with ccRCC

I'm Interested!

Please call
1-866-373-1464

A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

Sex: Any
Age: Adult (18 - 64), Older Adult (65+)
Accepting Healthy People: No
Type: Interventional / Therapeutic
Trial Phase: Phase I
Conditions Being Studied: Cancer - Kidney

Study Purpose

The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib in adult patients with confirmed advanced or metastatic clear cell Renal Cell Carcinoma who have experienced progression on or after prior anti-PD-1 or anti-PD-L1 immunotherapy.

Principal Investigator
Pedro Barata MD

Department/Division
Cancer (Thoracic)

UH IRB: 25-649;STUDY20251367 / Pro00091046
StudyID: ARCS1825
ClinicalTrials.gov: NCT07011719

I'm Interested!

Please call
1-866-373-1464

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-866-373-1464